Interní Med. 2010; 12(4): 212-217

Treatment and control of hypertension in Czech republic in period 1997/1998-2006/2009

MUDr.Marie Jozífová, prof.MUDr.Renata Cífková, CSc., MUDr.Zdenka Škodová, doc.MUDr.Věra Adámková, CSc., MUDr.Jan Bruthans, CSc., MUDr.Jiří Procházka, MUDr.Jiří Bělohoubek, MUDr.Markéta Galovcová, MUDr.Peter Wohlfahrt, MUDr.Alena Krajčoviechová, RNDr.Věra Lánská, CSc.
Pracoviště preventivní kardiologie, Oddělení lékařské statistiky, Institut klinické a experimentální medicíny, Praha

The study was designed to determine changes in the treatment and control of hypertension in a randomly selected population sample

of the Czech Republic over the past 10 years. The prevalence of hypertension rose in a random population sample of the Czech Republic

rose over the past 10 years while treatment and control of hypertension improved.

Keywords: hypertension, treatment of hypertension

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jozífová M, Cífková R, Škodová Z, Adámková V, Bruthans J, Procházka J, et al.. Treatment and control of hypertension in Czech republic in period 1997/1998-2006/2009. Interní Med. 2010;12(4):212-217.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2006/09. J Hypertens, odesláno do tisku.
    2. Zdravotnická statistika. Zemřelí 2008. ÚZIS, ČR, 2009.
    3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223. Go to original source...
    4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evolution and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252. Go to original source... Go to PubMed...
    5. Fagard RH, Van Den Endem, Leeman M, Warling X. Survey on treatment of hypertension and implementation of WHO/ ISH risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-1302. Go to original source... Go to PubMed...
    6. Erdine S. How well is hypertension controlled in Europe? J Hypertens 2000; 18: 1348-1350. Go to original source... Go to PubMed...
    7. Joffres MF, Ghadirian P, Fodor G, et al. Awareness, treatment and control of hypertension in Canada. Am J Hypertens 1999; 10: 1097-1102. Go to original source... Go to PubMed...
    8. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 14, 360(9349): 1903-1913. Go to original source... Go to PubMed...
    9. Jamerson K, Bakris G, Wun C, et al. Rationale and Design of the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome-effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17(9): 793-801. Go to original source...
    10. Widimský J jr, Cífková R, Špinar J, a kol. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství 2008; 1: 101-118.
    11. Mancia G, De Backer G, Dominiczak A, et al. Task Force Members 2007 Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-1187. Go to original source... Go to PubMed...
    12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317: 703-713. Go to original source...
    13. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with preventions stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
    14. Gerstein HC, Yusuf S, Mann JFE. Heart Outcomes Prevention Evolution (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    15. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139-1147. Go to original source... Go to PubMed...
    16. Hansson I, Zanchetti A, Carruthers SG, et al. On behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    17. Wald DS, Law M, Morris JK. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11000 Participants from 42 Trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    18. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1-94. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.